Clinical trial
Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or…
NCT00409214 · Light Sciences Oncology, Industry · Completed
Key facts
| NCT number | NCT00409214 |
|---|---|
| Title | Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma |
| Official title | A Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma (Defined for the Purposes of the Protocol as Anaplastic Astrocytoma [AA] or Glioblastoma Multiforme [GBM]) Using the Litx™ System to Confirm the Zone of Tumor Destruction During the… |
| Lead sponsor | Light Sciences Oncology, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma |
| Intervention type | Device, Drug, Procedure |
| Interventions | LS11 (talaporfin sodium), Light source (interstitial light emitting diodes), Intraoperative placement of device in glioma |
| Enrollment | 18 |
| Start date | Nov 1, 2006 |
| Primary completion | Feb 1, 2008 |
| First posted | Dec 8, 2006 |
| Last update posted | Nov 16, 2012 |
| Countries | Serbia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: